These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 29414021)

  • 1. Development and validation of a high-performance liquid chromatography method for the quantitation of intracellular PARP inhibitor Olaparib in cancer cells.
    Daumar P; Dufour R; Dubois C; Penault-Llorca F; Bamdad M; Mounetou E
    J Pharm Biomed Anal; 2018 Apr; 152():74-80. PubMed ID: 29414021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay quantifying olaparib in human plasma.
    Nijenhuis CM; Lucas L; Rosing H; Schellens JH; Beijnen JH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Dec; 940():121-5. PubMed ID: 24145016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validated stability indicating assay method of olaparib: LC-ESI-Q-TOF-MS/MS and NMR studies for characterization of its new hydrolytic and oxidative forced degradation products.
    Thummar M; Kuswah BS; Samanthula G; Bulbake U; Gour J; Khan W
    J Pharm Biomed Anal; 2018 Oct; 160():89-98. PubMed ID: 30075398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a simple high-performance liquid chromatography-ultraviolet detection method for olaparib in patients with ovarian cancer.
    Yasu T; Nishijima R; Ikuta R; Shirota M; Iwase H
    Drug Discov Ther; 2024 Jan; 17(6):428-433. PubMed ID: 38044120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of an integrated LC-MS/MS assay for therapeutic drug monitoring of five PARP-inhibitors.
    Bruin MAC; de Vries N; Lucas L; Rosing H; Huitema ADR; Beijnen JH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Feb; 1138():121925. PubMed ID: 31915109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and validation of a high-performance liquid chromatography method for the quantification of talazoparib in rat plasma: Application to plasma protein binding studies.
    Hidau MK; Kolluru S; Palakurthi S
    Biomed Chromatogr; 2018 Feb; 32(2):. PubMed ID: 28677821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours.
    Plummer R; Swaisland H; Leunen K; van Herpen CM; Jerusalem G; De Grève J; Lolkema MP; Soetekouw P; Mau-Sørensen M; Nielsen D; Spicer J; Fielding A; So K; Bannister W; Molife LR
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):723-9. PubMed ID: 26242220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel liquid chromatography method using diode-array detector for the determination of oleuropein in dietary supplements.
    Bertolini T; Vicentini L; Boschetti S; Andreatta P; Gatti R
    J Pharm Biomed Anal; 2016 Sep; 129():198-202. PubMed ID: 27429369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liquid chromatography-tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasma.
    Sparidans RW; Martens I; Valkenburg-van Iersel LB; den Hartigh J; Schellens JH; Beijnen JH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Jul; 879(21):1851-6. PubMed ID: 21622034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and Comparative Evaluation of Two Different Label-Free and Sensitive Fluorescence Platforms for Analysis of Olaparib: A Recently FDA-Approved Drug for the Treatment of Ovarian and Breast Cancer.
    Darwish IA; Khalil NY
    Molecules; 2023 Sep; 28(18):. PubMed ID: 37764300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy.
    Yuan Z; Chen S; Sun Q; Wang N; Li D; Miao S; Gao C; Chen Y; Tan C; Jiang Y
    Bioorg Med Chem; 2017 Aug; 25(15):4100-4109. PubMed ID: 28601509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative Characterization of Olaparib in Nanodelivery System and Target Cell Compartments by LC-MS/MS.
    Ottria R; Ravelli A; Miceli M; Casati S; Orioli M; Ciuffreda P
    Molecules; 2019 Mar; 24(5):. PubMed ID: 30862103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect and Mechanism of Radiosensitization of Poly (ADP-Ribose) Polymerase Inhibitor n Lewis Cells and Xenografts].
    Wang W; Duan B; Zeng L
    Zhongguo Fei Ai Za Zhi; 2016 Jan; 19(1):16-23. PubMed ID: 26805733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells.
    Shimo T; Kurebayashi J; Kanomata N; Yamashita T; Kozuka Y; Moriya T; Sonoo H
    Breast Cancer; 2014 Jan; 21(1):75-85. PubMed ID: 22454224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The expression of APE1 in triple-negative breast cancer and its effect on drug sensitivity of olaparib.
    Chen T; Liu C; Lu H; Yin M; Shao C; Hu X; Wu J; Wang Y
    Tumour Biol; 2017 Oct; 39(10):1010428317713390. PubMed ID: 29064327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined derivatization and high-performance liquid chromatography with fluorescence and ultraviolet detection for simultaneous analysis of octreotide and gabexate mesylate metabolite in human pancreatic juice samples.
    Carlucci G; Selvaggi F; Sulpizio S; Bassi C; Carlucci M; Cotellese R; Ferrone V; Innocenti P; Locatelli M
    Biomed Chromatogr; 2015 Jun; 29(6):911-7. PubMed ID: 25354693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.
    Gunderson CC; Moore KN
    Future Oncol; 2015; 11(5):747-57. PubMed ID: 25757679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to Olaparib.
    Dufour R; Daumar P; Mounetou E; Aubel C; Kwiatkowski F; Abrial C; Vatoux C; Penault-Llorca F; Bamdad M
    Sci Rep; 2015 Aug; 5():12670. PubMed ID: 26234720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
    Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.